Open AccessRadioiodine therapy for Graves disease as a risk factor of endocrine ophthalmopathy
Author(s) -
М. С. Шеремета,
И. М. Беловалова,
N. Yu. Sviridenko
Publication year - 2009
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl200955219-22
Subject(s) - medicine , adverse effect , incidence (geometry) , endocrine system , thyroid , hormone , graves' ophthalmopathy , thyroid stimulating hormone , gastroenterology , radioactive iodine , graves' disease , endocrinology , physics , optics
In 1973 and 1976 2 cases of endocrine ophthalmopathy (EO) after external irradiation of the anterior surface of the neck due to a tumor (Hodgkin's lymphoma) was described. Further observations showed that treatment of Graves' disease (BG) with radioactive iodine (131I) can worsen the course of EO. So, L. De Groot et al., Observing 264 patients after exposure to 131I for BG, found progression of EO in 4% of patients after the 1st course of therapy and in 12% after subsequent sessions.
Later the appearance or significant progression of EO in patients treated with 131I has been observed. Some studies have shown that the progression of EO after treatment with 131I without glucocorticoids administration can be observed in 18–30% of cases. Along with this, there is an opinion that 131I does not affect the incidence of clinical symptoms in the orbit and that hypothyroidism that occurs after it does not lead to the progression of eye symptoms. The relationship between treatment and the onset or progression of EO is not clear. Nevertheless, there is evidence of an adverse effect of an elevated level of antibodies to the thyroid stimulating hormone receptor in the blood serum after 131I training for EO.